dR. DAYAN GOODENOWE

FOUNDER, PRESIDENT & CEO - PRODROME SCIENCES, INC.

I do not believe that disease is either random or unpredictable. However, medicine, as it is currently practiced, is based upon this passive acceptance model. Passive, in that we primarily wait for disease to happen to us, and accepting in that we assume that we are powerless, in any specific way, to predict or prevent a specific disease prior to its occurrence.

The practice of medicine will not change from its current acute-care focus to a preventative-care focus by simply wishing it so. Our acute-care system, despite its faults, is practiced well and has systematically improved year after year. Each improvement must be targeted to an unmet need, be actionable, and have a measurable outcome. Only after these requirements are met will a change become accepted. This is the correct way to advance changes to any system.

My primary professional interest is the advancement of precision preventative medicine into mainstream medical practice. The achievement of this goal involves the integration and translation of various scientific and technological fields such as basic biochemistry, biomarker discovery, diagnostic technology, biostatistics, clinical trial design and execution, targeted therapeutic development, epidemiology, and healthcare economics. The prevention and treatment of neurodegenerative diseases is my primary focus.

As the founder of Prodrome Sciences Inc., my primary responsibility is to build a next-generation team of dedicated researchers and other professionals and to work with and continue to grow this team such that Prodrome Sciences Inc. can reach its ultimate goal of saving lives and improving quality of life by implementing our targeted strategy of disease prevention through prodrome detection and treatment. I am immensely proud of our founding team and consider myself fortunate to have this opportunity to build a new company with them.

POPULATION HEALTH

Population health is not about designing and executing narrowly defined clinical trials with very strict inclusion and exclusion criteria to determine if a drug or supplement can modify carefully controlled and selected disease symptoms.  These types of trials are important and invaluable to the scientific community and allow scientists to better understand certain biochemical mechanisms of disease.  However, the real human population is messy.  Population health is about designing and executing clinical trials for the real world and for real people living normal lives.  Population health is about changing disease incidence rates and epidemiological numbers.  

Bright Gradient

The solutions to Population Health, are only as good as the number of people who can access and derive a benefit from them. That is why their development requires effective community engagement. This means soliciting community support, engaging the community in feedback, using the community's experiences to optimize protocols, and most importantly, building trust. To do so, I offer: 

  • Solutions that people can understand 

  • Technology that is accessible and affordable 

  • Outcome measures that people can see and feel in themselves 

 

My efforts to achieve these objectives involve:  

  • Developing and expanding accessible blood testing technology for key, intervenable, chronic disease prodromes  

  • Developing accessible and measurable biochemical intervention protocols for specific indications like dementia and autism  

  • Partnering with online tracking systems that can be used by small and large community groups 

 

The solution to improving Population Health outcomes is to put as much power as possible in the hands of everyday people and engage them in being part of the solution. I am fortunate to have been able to develop a unique set of skills and technologies for investigating and researching the biochemical basis of disease.  However, to effectively apply these skills, I need to collaborate with other researchers who have their own unique skills which are complementary to my own.  I am privileged to have had the opportunity to work with numerous leading researchers from around the world on both clinical and laboratory research studies regarding the biochemical basis of health and disease.  Over the years, I have donated millions of dollars to foster academic collaborations on areas of health and disease. The results from these collaborations and my internally funded research programs form the basis of my population health strategy.  

research affiliates

Jonty Foundation

Our focus has been on the following:

  • Alzheimer's Disease

  • Schizophrenia

  • Bipolar Disorder

  • Unipolar Depression

  • Parkinson's Disease

  • Autism

  • Colon Cancer

  • Liver Cancer

  • Hepatitis Cirrhosis

  • Aging

  • Pancreatic Cancer

  • Gastric Cancer

  • ALS

  • Esophageal Cancer

  • Multiple Sclerosis

  • Breast Cancer

  • Cervical Cancer

  • Endometrial Cancer

  • Prostate Cancer

PATENTS

Plasmalogen Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treating Diseases of Aging Mediated by Plasmalogen Deficiency

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Treatment of Senile Dementia of the Alzheimer's Type

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Method of Visualizing Non-Targeted Metabolomic Data Generated from Fourier Transform Ion Cyclotron Resonance Mass Spectrometers

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Method and Apparatus for Fourier Transform Ion Cyclotron Resonance Mass Spectrometry

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Method of Non-Targeted Complex Sample Analysis

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Diagnosis, Risk Assessment, and Monitoring of Autism Spectrum Diseases

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Treatment of Elevated Cholesterol Levels (Method for Lowering Cholesterol)

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

Methods for the Diagnosis of Dementia and other Neurological Disorders

Issued September 19, 2006 Canada 2298181

Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.

My research into the biochemical mechanisms of disease started in 1990. My curiosity about the biochemistry of life is as insatiable
today as it was 30 years ago. In those 30 years, I have invented and developed advanced diagnostic and bioinformatic technologies,
designed and manufactured novel and natural biochemical precursors, and identified biochemical prodromes of numerous diseases including
Alzheimer’s disease and dementia, Parkinson’s disease, multiple sclerosis, stroke, autism, amyotrophic lateral sclerosis (ALS), multiple system atrophy, schizophrenia, bipolar disorder, depression, and cancers of the colon, pancreas, ovary, breast, lung, kidney, esophagus, liver, stomach, and endometria. I strive to go beyond the diagnosis of disease and I am setting my sights on figuring out how long the human body can maintain the physical and biological functions of life.

PROVEN SOLUTIONS

For HEALTH PROFESSIONALS

Dr. Goodenowe’s advanced biomarker testing technology is only available through certified practitioners. If you would like to become a certified practitioner, please click here. Dr. Goodenowe’s physician-grade formulary is available at prodrome.com or on fullscripts.

FOR CONSUMERS

Dr. Goodenowe’s advanced lab testing and physician grade supplements are only available at Prodrome.com and through licenced practitioners. Click here to see if your doctor is registered. Dr. Goodenowe has authorized PerfectPlasmalogens to offer his most popular brain health supplement combinations here.

LET'S CONNECT ON YOUR HEALTH JOURNEY
  • Facebook
  • Instagram

© 2020 Dr. Dayan Goodenowe